Zanubrutinib exhibits PFS benefit in relapsed/refractory CLL/SLL: topline results from the ALPINE trial

Topline results obtained from final progression-free survival analysis (PFS) of the phase III ALPINE trial (NCT03734016) indicate that zanubrutinib is efficacious and well tolerated in previously treated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).¹

ALPINE is a global, randomized, phase III study of zanubrutinib versus ibrutinib in 652 patients with previously treated R/R CLL or SLL. The trial met all of its primary and secondary endpoints, with safety and final PFS analysis consistent with that of prior reports. This data adds weight to the growing body of evidence that zanubrutinib could provide a safe and effective treatment option for patients with R/R CLL and SLL.